Skip to main content
. 2014 Apr 2;5(9):2688–2702. doi: 10.18632/oncotarget.1883

Figure 6. Vandetanib impairs NB growth in vivo.

Figure 6

(A) Left panel, MYCN/KI AlkR1279Q mice were treated for 10 days with control (n=8), crizotinib (n=11) or vandetanib (n=8); right panel, MYCN/KI AlkF1178L mice were treated for 10 days with control (n=5) or vandetanib (n=6). Treatment efficacy was determined by measuring tumor weight at sacrifice. (B) and (C) The Ret expression level was investigated by Western blot in MYCN/KI AlkR1279Q and MYCN/KI AlkF1178L treated tumors and controls using the anti-Ret antibody EPR2871 (Abcam). Actin was used as a standard for quantification.